Global Japanese Encephalitis Market

Global Japanese Encephalitis Market is expected to reach $2.3 Bn by 2032 from $1.58 Bn in 2025, at a CAGR of 5.5 % during forecast period.

Global Japanese Encephalitis Market Overview:

Japanese encephalitis is a virus spread by mosquitos. The Japanese encephalitis virus causes a brain infection known as Japanese encephalitis (JE). Brain inflammation does occur on occasion. Other symptoms include headaches, vomiting, fever, confusion, and seizures in these cases.

Global Japanese Encephalitis Market Dynamics:

Rising prevalence of viral encephalitis is the major factor driving the market growth.

The growth of this market is due to the rising prevalence of Japanese encephalitis diseases around the world. The market is driven by an increase in cases of mosquito-borne flavivirus diseases. It is caused by a flavivirus spread by mosquitos, which belongs to the same family as yellow fever, dengue fever, and West Nile viruses. The virus is present in pigs and birds, and it is spread to humans by mosquito bites from infected Culex species. Furthermore, increased understanding of Japanese encephalitis vaccination by WHO and government officials, as well as an increase in the incidence of yellow fever, dengue, and West Nile viruses are expected to boost the market growth. The World Health Organization states that, JE affects about 68000 people worldwide in a year. During the forecast era, one of the major growth drivers for the market will be the inclusion of vaccination against Japanese encephalitis in national immunization plans.

During the forecast period, factors such as stringent government regulation regarding efficacy and safety, lack of knowledge and lack of vaccine supply in remote areas may be the major restraining factors for the global Japanese encephalitis vaccine market.

The report has profiled fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Japanese Encephalitis Market Segment Analysis:

The Global Japanese Encephalitis Market is segmented on the basis of diagnosis and Vaccine Type,

Based on diagnosis, the IgM Capture ELISA test segment is expected to dominate the global market during the forecast period. IgM antibodies to the JE virus are normally detectable 3 to 8 days after the onset of illness and last 30 to 90 days, though longer persistence has been recorded. As a result, positive IgM antibodies can sometimes indicate a previous infection or vaccination.

Based on Vaccine Type, Inactivated Vero-cell derived vaccine segment is expected to account for the largest share during the forecast period. Since mouse brain-derived vaccines are being replaced by cell-based vaccines due to higher effectiveness, safety, and animal ethical regulations, the Vero cell-derived vaccine segment is expected to account for a XX% share of the market during the forecast period. There are approximately seven vaccines approved, which contributes to the dominant market share held by inactivated vaccines. This is due to the growing number of inactivated vaccine options available and their high efficacy in treating the indication.

To know about the Research Methodology :- Request Free Sample Report

Global Japanese Encephalitis Market Regional Insights:

Asia Pacific is expected to hold the largest the market share during forecast period.

Due to the high prevalence of JE, government-mandated immunization programmes, increasing investment in R&D, entry of new vaccine manufacturers in countries such as India and China, increased number of travellers in the area, medical tourism, and other factors, The Asia Pacific is anticipated to be the most lucrative market. Vaccination is a key component of UNICEF, WHO, and Gavi's efforts to stop the disease from spreading. The addition of vaccination against Japanese encephalitis to India's Universal Immunization Program in 2014 resulted in a substantial increase in vaccination does procurement. In other Asian countries, such initiatives are becoming more popular.

The report also helps in understanding Global Japanese Encephalitis Market dynamics, structure by analyzing the market segments and project the Global Japanese Encephalitis Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Japanese Encephalitis Market make the report investor’s guide.

Global Japanese Encephalitis Market Scope: Inquire before buying

Global Japanese Encephalitis Market, By Region:

• North America
• Europe
• South America
• MEA
• APAC

Global Japanese Encephalitis Market, Key players:

• Takeda Pharmaceutical Company Limited
• Sanofi Pasteur
• Bharat Biotech International Limited
• GlaxoSmithKline plc
• Sinovac Biotech Ltd
• Valneva SE
• Biological E Limited
• Panacea Biotec
• Serum Institute of India Pvt Ltd
• Merck and Co Inc
• Pfizer Inc
• Novartis AG
• China National Pharmaceutical Group Sinopharm
• Chengdu Institute of Biological Products
• Liaoning Chengda Biotechnology Co Ltd
• Shanghai Institute of Biological Products
• Wuhan Institute of Biological Products
• Beijing Tiantan Biological Products
• Changchun Institute of Biological Products
• Zhejiang Tianyuan Bio Pharmaceutical
• Hualan Biological Engineering Inc
• Indian Immunologicals Limited
• Green Cross Corporation
• KM Biologics Co Ltd
• Biken Co Ltd
• Imaxio
• Xiamen Amoytop Biotech Co Ltd
• Haffkine Bio Pharmaceutical Corporation Ltd
• Shenzhen Kangtai Biological Products Co Ltd
• Research Foundation for Microbial Diseases of Osaka University